Executive Summary
Generated July 30, 2026
Healthcare & Life Sciences
Intellia Therapeutics
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Accelerating
Activity
2 recorded changes in the last 90 days
Steady
Momentum
insider filing activity unchanged since last check
Headquarters
Cambridge, Massachusetts, USA
Website
Listing
NTLA · NASDAQ
Market Cap
$1.52B
Revenue (TTM)
$66.09M
Price
USD10.89 (-5.06%)
Market data as of Jul 29, 2026, 11:25 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
Intellia Therapeutics is a CRISPR gene-editing company that reported Phase 3 success in April 2026 for lonvo-z, an in vivo CRISPR therapy that inactivates a liver gene to reduce hereditary angioedema (HAE) swelling attacks -- an 87% reduction in attack rate versus placebo across an 80-patient study, with 62% of treated patients attack-free and therapy-free versus 11% on placebo. Intellia has begun a rolling FDA submission seeking approval of what could become the first in vivo gene-editing therapy to reach market for any disease, targeting a 2027 launch if approved, with a favorable safety profile limited mainly to infusion-related reactions, headaches and fatigue.
Strategic Connections
- Gene Editing & Longevity Biotech: Intellia's lonvo-z is on track to become the first approved in vivo CRISPR gene-editing therapy for any disease, a landmark validation of the gene-editing therapeutics category.
- Healthcare & Life Sciences: Intellia's CRISPR gene-editing therapeutics are part of the broader healthcare and life sciences industry's shift toward genetic-medicine treatment modalities.
- CRISPR Therapeutics: Intellia Therapeutics competes with CRISPR Therapeutics in the clinical-stage gene-editing therapeutics space, both pursuing in vivo and ex vivo CRISPR approaches.
Strategic Risks
- As a first-in-category in vivo gene-editing therapy, lonvo-z faces novel regulatory scrutiny with no direct approval precedent to draw on
- Long-term durability and safety of permanent gene-editing interventions remain to be established through post-market surveillance
Future Outlook
- Potential 2027 FDA approval and launch of lonvo-z as the first in vivo CRISPR gene-editing therapy for any disease
- Platform expansion into additional liver-mediated genetic diseases beyond hereditary angioedema using the same in vivo CRISPR delivery approach
Sources
2 sources, 49% average source confidence — full citations in the Full Analyst Report.
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Executive Summary — switch to the Full Analyst Report.